Background: Development of long-lasting anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) T-cell responses in persons with multiple sclerosis (pwMS) treated with ocrelizumab is questioned. Objective: Investigate antiviral T-cell responses after infection with SARS-CoV-2 in ocrelizumab-treated pwMS. Control groups included ocrelizumab-treated pwMS without SARS-CoV-2 infection, and non-MS individuals with and without SARS-CoV-2 infection. Methods: Peripheral blood mononuclear cells were stimulated with SARS-CoV-2 peptide pools and T-cell reactivity was assessed by ELISPOT for interferon (IFN)-gamma detection, and by multiparametric fluorescence-activated cell sorting (FACS) analyses for assessment and characterization of T-cell activation. Results: ELISPOT assay against the spike and the N protein of SARS-CoV-2 displayed specific T-cell reactivity in 28/29 (96%) pwMS treated with ocrelizumab and infected by SARS-CoV-2, similar to infected persons without MS. This reactivity was present 1 year after infection and independent from the time of ocrelizumab infusion. FACS analysis following stimulation with SARS-CoV-2 peptide pools showed the presence of activation-induced markers (AIMs) in both CD4(+) and CD8(+) T-cell subsets in 96% and 92% of these individuals, respectively. Within naive AIM(+) CD4(+) and CD8(+) T-cells, we detected T memory stem cells, suggesting the acquisition of long-term memory. Conclusions: B-cell depletion using ocrelizumab does not impair the development of long-lasting anti-SARS-CoV-2 T-cell responses.

Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumab-treated MS patients / Guerrera, Gisella; Mandelli, Alessandra; Finardi, Annamaria; Orrico, Mario; D'Orso, Silvia; Picozza, Mario; Noviello, Maddalena; Beretta, Valeria; Bonetti, Bruno; Calabrese, Massimiliano; Marastoni, Damiano; De Rossi, Nicola; Capra, Ruggero; Salvetti, Marco; Buscarinu, Maria Chiara; Inglese, Matilde; Uccelli, Antonio; Moiola, Lucia; Raposo, Catarina; Muros-Le Rouzic, Erwan; Pedotti, Rosetta; Filippi, Massimo; Bonini, Chiara; Battistini, Luca; Borsellino, Giovanna; Furlan, Roberto. - In: MULTIPLE SCLEROSIS. - ISSN 1352-4585. - 28:12(2022), pp. 1937-1943. [10.1177/13524585221102158]

Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumab-treated MS patients

Orrico, Mario;Filippi, Massimo;Bonini, Chiara;Furlan, Roberto
2022-01-01

Abstract

Background: Development of long-lasting anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) T-cell responses in persons with multiple sclerosis (pwMS) treated with ocrelizumab is questioned. Objective: Investigate antiviral T-cell responses after infection with SARS-CoV-2 in ocrelizumab-treated pwMS. Control groups included ocrelizumab-treated pwMS without SARS-CoV-2 infection, and non-MS individuals with and without SARS-CoV-2 infection. Methods: Peripheral blood mononuclear cells were stimulated with SARS-CoV-2 peptide pools and T-cell reactivity was assessed by ELISPOT for interferon (IFN)-gamma detection, and by multiparametric fluorescence-activated cell sorting (FACS) analyses for assessment and characterization of T-cell activation. Results: ELISPOT assay against the spike and the N protein of SARS-CoV-2 displayed specific T-cell reactivity in 28/29 (96%) pwMS treated with ocrelizumab and infected by SARS-CoV-2, similar to infected persons without MS. This reactivity was present 1 year after infection and independent from the time of ocrelizumab infusion. FACS analysis following stimulation with SARS-CoV-2 peptide pools showed the presence of activation-induced markers (AIMs) in both CD4(+) and CD8(+) T-cell subsets in 96% and 92% of these individuals, respectively. Within naive AIM(+) CD4(+) and CD8(+) T-cells, we detected T memory stem cells, suggesting the acquisition of long-term memory. Conclusions: B-cell depletion using ocrelizumab does not impair the development of long-lasting anti-SARS-CoV-2 T-cell responses.
2022
COVID-19
SARS-CoV-2
anti-CD20
cellular immune response
multiple sclerosis
ocrelizumab
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/131258
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact